Median serum concentrations of (A) interleukin-6 (IL-6), (B) IL-8, and (C) IL-10 in patients with indolent non-Hodgkin lymphoma after once-per-week administration of 1,000 mg obinutuzumab or 375 mg/m2 rituximab during the four-cycle induction period. C, cycle; D, day; End, end of infusion; Mid, midinfusion; Post, postinfusion; Pre, preinfusion.